Citations

Showing 10 of 108104 citations.

Utilization of Anterolateral Thigh Flap and Transverse Cervical Recipient Vessels for Head and Neck Cancer Patients With Former Neck Dissection and Irradiation
Lin, Kuan-Wen , Huang, Tony Chieh‐Ting , Cheng, Hsu-Tang

Mayo Clinic

Annals of Plastic Surgery | December 5, 2018 | Volume: 82 | Issue: 4 | Pages: 415-419

10.1097/sap.0000000000001647 | PMID 30516556 Get It

PurposeFree flap reconstruction in head and neck cancer patients with prior tumor resection, neck dissection, and irradiation is clinically challenging. The purpose of this study was to investigate the reliability and outcome of using the anterolateral thigh (ALT) flap and transverse cervical recipient vessels for microvascular reconstruction in patients with depleted vessels in the head and neck region caused by previous surgery and irradiation.MethodsBetween January 2015 and December 2017, microsurgical head and neck reconstruction was performed using the ALT flap and transverse cervical artery (TCA) as the recipient vessel in 15 patients who had undergone previous neck dissections and irradiation for cancer treatment. All patients had a “vessel-depleted neck” resulting from severe scarring and radiation fibrosis. Clinical data of each patient were recorded.ResultsAll ipsilateral TCAs were found to be damage free. Subsequently, free ALT flaps were revascularized using the TCAs. One patient developed venous thrombosis, and another patient developed arterial thrombosis. They were both salvaged within 6 hours postoperatively. No flap failure or mortalities were reported within the 30-day postoperative period. Two patients developed orocutaneous fistula and were further managed with wound care. The mean follow-up time was 11.9 ± 6.0 months (range, 5–23 months). Five patients died during the follow-up period from cancer progression.ConclusionsThe use of the free ALT flap and TCA as the recipient vessel provides favorable microsurgical outcomes in patients with depleted recipient vessels in the head and neck region caused by previous neck dissections and radiation therapy.
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1
Block, Matthew S. , Nevala, Wendy K. , Pang, Yuan‐Ping , Allred, Jacob B., Strand, Carrie , Pang, Yuan-Ping , Markovic, Svetomir N.

Mayo Clinic

Melanoma Research | December 5, 2018 | Volume: 29 | Issue: 4 | Pages: 420-427

10.1097/cmr.0000000000000556 | PMID 30520800 Get It

A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote epitope spreading) and/or resiquimod (to activate antigen-presenting cells). HLA-A2-positive patients with resected stage II, III, and IV melanoma were assigned to treatment on one of three schedules. All patients received three subcutaneous doses of the peptide MART-1a mixed with Montanide. In addition, patients on schedule 1 received the xenoantigen peptide Gag267–274, patients on schedule 2 received topical resiquimod, and patients on schedule 3 received both Gag267–274 and resiquimod. Blood samples were tested for the frequency of antigen-specific T cells by tetramer assay, as well as immune cell subtypes and plasma cytokine levels. Patients enrolled from October 2012 to December 2014, with 10 patients enrolling to each schedule. The most common adverse events were injection site reaction (26 patients) and fatigue (15 patients). Tetramer analysis revealed antigen-specific responses (defined as doubling of MART-1a-specific T cells from pretreatment to post-treatment) in 20, 60, and 40% of patients treated on schedules 1, 2, and 3, respectively. Vaccine treatment consisting of MART-1a peptide, Gag267–274, Montanide, and topical resiquimod was well-tolerated. The addition of the Gag267–274 xenoantigen was not associated with an increase in the response to MART-1a, whereas use of topical resiquimod was associated with a higher frequency of MART-1a-specific T-cell responses that did not meet statistical significance.
Cumulative network-meta-analyses, practice guidelines and actual prescriptions of drug treatments for postmenopausal osteoporosis: a study protocol for cumulative network meta-analyses and meta-epidemiological study
Kataoka, Yuki , Luo, Yan , Chaimani, Anna , Ōnishi, Akira , Kimachi, Miho , Tsujimoto, Yasushi , Murad, M. Hassan , Li, Tianjing , Cipriani, Andrea , Furukawa, Toshi A. , Murad, Mohammad Hassan, Murad, M Hassan , Furukawa, Toshi A

Mayo Clinic

BMJ Open | December 5, 2018 | Volume: 8 | Issue: 12 | Pages: e023218

10.1136/bmjopen-2018-023218 | PMID 30518583 Get It

Introduction Cumulative network meta-analysis (NMA) is a method to provide a global comparison of multiple treatments with real-time update to evidence users. Several studies investigated the ranking of cumulative NMA and the recommendations of practice guidelines. However, to the best of our knowledge, no study has evaluated the cumulative NMA ranking and prescription patterns. Here, we present a protocol for a meta-epidemiological investigation to compare the results of cumulative NMA with the recommendations in postmenopausal osteoporosis practice guidelines and with the actual prescriptions. Method and analysis We will use the data of primary trials from the upcoming postmenopausal osteoporosis clinical practice guideline of the Endocrine Society. We will conduct cumulative NMA using all eligible trials and generate hierarchy of treatment rankings by using the surface under the cumulative ranking curve. We will search practice guidelines in relevant society websites. Two review authors will extract the practice recommendations. We will use data from the Medical Expenditures Panel Survey, a US representative sample of the non-institutionalised population, to determine the prescription patterns. Ethics and dissemination Because all data will be retrieved from public databases, institutional review board approval is not required. We will publish our findings in a peer-reviewed journal and present key findings at conferences. Trial registration number UMIN000031894: Pre-results.
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, Deli , Fritz, Andrew J. , Gordon, Jonathan A. R., Tracy, Kirsten M. , Frietze, Seth , Carr, Frances E. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Zaidi, Sayyed K. , Lian, Jane B. , Stein, Janet L. , Tracy, Kirsten M , van Wijnen, Andre J , Stein, Gary S , Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | December 5, 2018 | Volume: 234 | Issue: 6 | Pages: 8597-8609

10.1002/jcp.27841 | PMID 30515788 Get It

AbstractThe RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context‐dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial‐to‐mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context‐dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.
The Effects of Speech Compression Algorithms on the Intelligibility of Two Individuals With Dysarthric Speech
Sandoval, Steven , Berisha, Visar , Lansford, Kaitlin L. , Utianski, Rene L. , Liss, Julie , Berisha, Visar

Mayo Clinic

American Journal of Speech-Language Pathology | December 5, 2018 | Volume: 28 | Issue: 1 | Pages: 195-203

10.1044/2018_ajslp-18-0081 | PMID 30515518 Get It

Purpose Telemedicine, used to offset disparities in access to speech-language therapy, relies on technology that utilizes compression algorithms to transmit signals efficiently. These algorithms have been thoroughly evaluated on healthy speech; however, the effects of compression algorithms on the intelligibility of disordered speech have not been adequately explored. Method This case study assessed acoustic and perceptual effects of resampling and speech compression (i.e., transcoding) on the speech of 2 individuals with dysarthria. Forced-choice vowel identification and transcription tasks were utilized, completed by 20 naive undergraduate listeners. Results Results showed relative improvements and decrements in intelligibility, on various measures, based on the speakers' acoustic profiles. The transcoding of the speech compression algorithm resulted in an enlarged vowel space area and associated improvements in vowel identification for 1 speaker and a smaller vowel space area and decreased vowel identification for the other speaker. Interestingly, there was an overall decrease in intelligibility in the transcription task in this condition for both speakers. Conclusions There is a complex interplay between dysarthria and compression algorithms that warrants further exploration. The findings suggest that it is critical to be mindful of apparent changes in intelligibility secondary to compression algorithms necessary for practicing telemedicine. Supplemental Material https://doi.org/10.23641/asha.7291940
Management of post‐myocardial infarction ventricular septal defects: A critical assessment
Omar, Sabry , Morgan, Garrison L., Thourani, Vinod H. , Rihal, Charanjit S. , Patel, Ruchi , Kherada, Nisharahmed, Egbe, Alexander C. , Beohar, Nirat , Panchal, Hemang B. , Rihal, Charanjit S.

Mayo Clinic

Journal of Interventional Cardiology | December 5, 2018 | Volume: 31 | Issue: 6 | Pages: 939-948

10.1111/joic.12556 | PMID 30318677 Get It

Background Post‐myocardial infarction (MI) ventricular septal defects (PIVSD) are an uncommon but life‐threatening complication of acute MI. Although surgical closure has been the standard of care, mortality, and recurrence of VSD remain high even after emergent surgery. Transcatheter VSD closure (TCC) devices have become an alternative or adjunct to surgical closure. Methods Online database search was performed for studies that included adults with PIVSD who underwent medical treatment (MT) alone, surgical closure (SC) (early or late), and TCC (early, late, or for post‐surgical residual VSD). Results Twenty‐six studies were included with a total of 737 patients who underwent either MT ( N = 100), SC (early ( n = 167), late ( n = 100)), and TCC (early ( n = 176), late ( n = 115), or post‐surgical residual VSD ( n = 79)). The 30‐day mortality among MT group was 92 ± 6.3%, among SC was 61 ± 22.5% (early 56 ± 23%, late 41 ± 30%), and for all TCC patients was 33 ± 24% (early 54 ± 32.7%, late 16 ± 26%), and TCC for post‐surgical residual VSD 11 ± 34.9%. The mortality among overall SC, overall TCC and early TCC groups was significantly lower as compared with the MT ( P < 0.001 for all comparisons). The overall mortality among all TCC, and late TCC groups was significantly lower when compared with the late SC ( P < 0.0001, P < 0.0001, respectively). Conclusion Closure of PIVSD decreases mortality as compared with MT alone and should be attempted as early as possible after diagnosis. Selection of TCC versus SC should be based on factors including complexity of the defect, availability of closure devices, expertise of the operator, and clinical condition of patient.
Assessing the incidence trend and characteristics of eosinophilic esophagitis in children in Olmsted County, Minnesota
Hommeida, Salim, Grothe, Rayna, Hafed, Yamen, Lennon, Ryan J. , Schleck, Cathy D. , Alexander, Jeffrey A. , Katzka, David A. , Absah, Imad

Mayo Clinic

Diseases of the Esophagus | December 5, 2018 | Volume: 31 | Issue: 12 | Pages: No page available

10.1093/dote/doy062 | PMID 29982568 Get It

Fiddler's Neck: A Review
Myint, Calvin , Rutt, Amy L. , Sataloff, Robert T.

Mayo Clinic

Ear, Nose & Throat Journal | December 4, 2018 | Volume: 96 | Issue: 2 | Pages: 76-79

10.1177/014556131709600210 | PMID 28231367 Get It

Fiddler's neck is a common dermatologic condition associated with instrument use in violin and viola players. It typically manifests as a submandibular and/or supraclavicular lesion. It is a benign condition, but it may be mistaken for lymph-edema or a salivary gland malignancy. Otolaryngologists who treat patients with fiddler's neck should be aware of appropriate management protocols and the need to avoid surgical excision. We obtained informed consent from 3 violinists to present their cases as specific examples of fiddler's neck. In addition, we present a literature review based on our PubMed search for articles about this instrument-induced dermatitis. The literature suggests that submandibular fiddler's neck is caused by mechanical pressure and shear stress on the skin and that it can present as erythema, scarring, edema, and lichenification. Supraclavicular fiddler's neck, on the other hand, is caused by allergic contact dermatitis, and it can present as an eczematous, scaly, and/or vesicular lesion. In most cases, a good history (especially of string instrument use), physical examination, and a patch test are sufficient to diagnose this condition. Management of fiddler's neck includes a topical steroid, proper instrument handling, neck padding, changing the instrument's materials, and/or reducing the amount of playing time. Surgical excision is usually not advisable.
Invasive Fungal Laryngopharyngitis Resulting in Laryngeal Destruction with Complete Laryngotracheal Separation: Report of a Case
Swiss, Tyler P., Cervantes, Sergio S., Hinni, Michael, Lott, David G.

Mayo Clinic

Ear, Nose & Throat Journal | December 4, 2018 | Volume: 96 | Issue: 1 | Pages: E33-E36

10.1177/014556131709600105 | PMID 28122110 Get It

As the treatment of hematopoietic cancers evolves, otolaryngologists will see a higher incidence of opportunistic infections. We discuss a case of invasive fungal disease that invaded the larynx, pharynx, trachea, and pulmonary parenchyma after chemotherapy. The patient, a 46-year-old woman, presented 1 week after undergoing induction chemotherapy. Her initial symptoms were odynophagia and dysphagia. Despite encouraging findings on physical examination, her health rapidly declined and she required an urgent tracheotomy and multiple operations to address spreading necrosis. Because of her inability to heal, she was not a candidate for laryngectomy, so she was treated with conservative management. The patient was then lost to follow-up, but she returned 5 months later with laryngeal destruction and a complete laryngotracheal separation. While noninvasive fungal laryngitis is routinely encountered, its invasive counterpart is rare. The literature demonstrates that some cases completely resolve with medical therapy alone but that surgery is necessary in others. We recommend surgical debridement of all necrotic tissue.
Synchronous Lesions of the Right Accessory Parotid Gland and Left Main Parotid Gland
Nguyen, Ba D.

Mayo Clinic

Ear, Nose & Throat Journal | December 4, 2018 | Volume: 96 | Issue: 6 | Pages: 200-203

10.1177/014556131709600617 | PMID 28636728 Get It